New Drug Application Initiated with U.S. FDA for TAR-200, the First and Only Intravesical Drug Releasing System for Patients with BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer January ...
Gautam Jayram discusses key updates in bladder and kidney cancer management. Topics include intermediate-risk bladder cancer, BCG-unresponsive disease, immunotherapy for muscle-invasive bladder cancer ...
IBCN 2024: Quantifying Intra-tumoral Molecular Subtype Heterogeneity in MIBC from Histological Slides using a deep learning approach in the VESPER Trial IBCN 2024: Oncolytic Virotherapy Expressing a ...
Rashid Sayyid and Zach Klaassen discuss a study published in Lancet Oncology titled, “Radical Cystectomy versus Trimodality Therapy for Muscle-Invasive Bladder Cancer: A Multi-Institutional Propensity ...
WCET 2022: Assessing the Clinical Force Threshold for the Safe Deployment of a Ureteral Access Sheath Using a Ureteral Access Sheath Force Sensor. WCET 2022: Assessing the Impact Of Irrigation ...
To investigate the expression patterns of Nectin-4, the target molecule of the antibody-drug conjugate enfortumab vedotin (EV), in relation to histological and molecular subtypes of urothelial bladder ...
Small renal masses (SRM), especially those under 7 cm pose significant diagnostic challenges when using conventional imaging (CT/MRI). PET/CT with [89Zr]Zr-girentuximab offers a promising alternative ...
ASTRO 2021: 10-Year Results of a Phase III Randomized Trial of High-Dose Radiotherapy and Risk-Adapted Androgen Deprivation Therapy in Localized Prostate Cancer ASTRO 2021: Impact of AR-V7 and Other ...
Penile cancer is a rare malignancy treated via various surgical techniques guided by disease stage and grade with current guidelines suggesting partial or total penectomy for those with pT2 or greater ...